Susceptibility of Helicobacter pylori to antimicrobial agents: effect of ebrotidine and ranitidine.
Convincing evidence now exists that infection with H. pylori is a primary factor in the pathogenesis of gastric disease, and new therapy regimens include a combination of H2 blockers with antimicrobial agents. In this study, was assessed the effect of ebrotidine and ranitidine on the in vitro anti-H. pylori activity of amoxicillin, erythromycin, tetracycline, and metronidazole. The assays of the antiulcer drugs alone gave MIC value of 150 mg/L for ebrotidine and 1600 mg/L for ranitidine. Inclusion of ebrotidine in the antimicrobial agent assays evoked at its optimal concentration of 75 mg/L a 28% enhancement in the MIC of metronidazole, 2.5-fold enhancement in the MIC of erythromycin, 2-fold in amoxicillin and 1.7-fold in tetracycline, while ranitidine caused noticeable changes in the MIC values of the tested antimicrobial agents only a the dose of 1600 mg/L. The results demonstrate that ebrotidine enhances anti-H. pylori activity of antimicrobial agents at doses well below that of ranitidine.
Piotrowski
J
J
Research Center, University of Medicine and Dentistry of New Jersey, Newark, USA.
Piotrowski
E
E
Slomiany
A
A
Slomiany
B L
BL
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001557:Benzenesulfonates / Q000494:pharmacology*; D004347:Drug Interactions; D016480:Helicobacter pylori / Q000187:drug effects*; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D011899:Ranitidine / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D001557:Benzenesulfonates; D006635:Histamine H2 Antagonists; D013844:Thiazoles; D011899:Ranitidine; C075156:ebrotidine